Together, this supports a model where CSF T‐tau and P‐tau primarily behave as disease state markers in AD, indicating the presence of the AD process, while 18F‐AV‐1451 primarily behave as a disease stage marker, with continuous build‐up throughout the clinical stages of the disease. Here, MAPT is linked to Alzheimer disease.